VEGFA and glioblastoma: This system successfully delivered an anti-VEGFA siRNA into CXCR4+ endothelial and glioblastoma cells, reducing VEGF secretion and inhibiting endothelial cells migration, validating this strategy as a promising anti-angiogenic therapy [265].